Add like
Add dislike
Add to saved papers

Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.

Leukemia & Lymphoma 2020 January
It is a matter of debate whether myeloma patients with progressive disease (PD) after induction should receive salvage therapy or proceed directly to autologous stem cell transplantation. We performed a retrospective analysis of 1599 patients treated between 1991 and 2016 at the University Hospital of Heidelberg and other centers. Deepening of response through salvage therapy did not lead to better progression-free or overall survival (PD versus salvage therapy patients: HR  = 0.71, 95% CI [0.28, 1.80], p  = 0.5 and HR  = 0.77, 95% CI [0.30, 1.95], p  = 0.6, respectively), neither in patients treated with novel agents ( HR  = 0.66, 95% CI [0.23, 1.85], p  = 0.4 and HR  = 0.76, 95% CI [0.27, 2.15], p  = 0.6) nor older regimens ( HR  = 0.86, 95% CI [0.36, 2.07], p  = 0.7 and HR  = 0.8, 95% CI [0.34, 1.91], p  = 0.6). Therefore, primary nonresponders might benefit from a direct transplant rather than salvage induction, although the analyzed salvage therapy cohort was small ( n  = 23) and cytogenetics was not included in the multivariable analysis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app